← Back to Clinical Trials
Recruiting NCT06628453

NCT06628453 CGM for Management of Type 2 Diabetes in Pregnancy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06628453
Status Recruiting
Phase
Sponsor University of Alabama at Birmingham
Condition Type 2 Diabetes Mellitus (T2DM)
Study Type INTERVENTIONAL
Enrollment 564 participants
Start Date 2025-04-08
Primary Completion 2029-02

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 50 Years
Study Type INTERVENTIONAL
Interventions
CGM

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 564 participants in total. It began in 2025-04-08 with a primary completion date of 2029-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to learn if continuous glucose monitoring works better than self-monitoring of blood glucose (fingersticks) to treat type 2 diabetes in pregnancy. It will also learn about all risk factors (biologic, personal, social) for maternal and infant complications in type 2 diabetes pregnancies. The main questions it aims to answer are: 1. Does continuous glucose monitoring improve infant outcomes compared to self-monitoring of blood glucose? 2. Does continuous glucose monitoring improve maternal diabetes control and other maternal outcomes compared to self-monitoring of blood glucose? 3. What other factors increase the risk of maternal and infant complications? Participants will: 1. Use continuous glucose monitoring or self-monitoring of blood glucose to monitor blood sugar control from enrollment until delivery 2. Have blood drawn at enrollment, 24 weeks, 34 weeks and delivery to measure hemoglobin A1c levels and store blood for future analysis 3. Complete surveys about social support, environmental stressors, diabetes distress and glucose monitoring satisfaction at research visits 4. Have umbilical cord blood collected at delivery for analysis

Eligibility Criteria

Inclusion Criteria: * Type 2 diabetes mellitus treated with daily insulin injections or oral hypoglycemic agents diagnosed before pregnancy or at less than 14 weeks gestation with hemoglobin A1c 6.5% or greater * Pregnant with viable fetus at 6 to less than 23 weeks gestation * Maternal age 18-50 years old Exclusion Criteria: * Unable or unwilling to wear CGM due to intolerance to medical-grade adhesives or skin conditions * Multiple gestation * Major fetal anomaly or two or more minor fetal anomalies * Planned delivery outside study consortium * Participating in another conflicting interventional study * Participation in this trial in a previous pregnancy * Patient unable to consent * Physician refusal for other reasons

Contact & Investigator

Central Contact

Ashley Battarbee, MD, MSCR

✉ anbattarbee@uabmc.edu

📞 205-975-2361

Principal Investigator

Ashley Battarbee, MD, MSCR

PRINCIPAL INVESTIGATOR

University of Alabama at Birmingham

Frequently Asked Questions

Who can join the NCT06628453 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 50 Years, studying Type 2 Diabetes Mellitus (T2DM). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06628453 currently recruiting?

Yes, NCT06628453 is actively recruiting participants. Contact the research team at anbattarbee@uabmc.edu for enrollment information.

Where is the NCT06628453 trial being conducted?

This trial is being conducted at Birmingham, United States, San Diego, United States, Chapel Hill, United States, Portland, United States and 3 additional locations.

Who is sponsoring the NCT06628453 clinical trial?

NCT06628453 is sponsored by University of Alabama at Birmingham. The principal investigator is Ashley Battarbee, MD, MSCR at University of Alabama at Birmingham. The trial plans to enroll 564 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology